GSK Says Health Canada Expands Jemperli Plus Chemotherapy Approval
April 17 (Reuters) - GSK plc GSK.L:
GSK: HEALTH CANADA EXPANDS JEMPERLI PLUS CHEMOTHERAPY APPROVAL TO ALL ADULT PATIENTS WITH PRIMARY ADVANCED OR FIRST RECURRENT ENDOMETRIAL CANCER
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey







